Clinical Trials on Inflammatory Breast Carcinoma in Germany
Total 2646 results
-
German Breast GroupRoche Pharma AG; Celgene CorporationCompletedInflammatory Breast Cancer | HER-2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III | Inflammatory Breast Cancer Stage IVGermany
-
German Breast GroupCelgene Corporation; AmgenCompletedInflammatory Breast Cancer | HER2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage IIIGermany
-
German Breast GroupGlaxoSmithKline; Roche Pharma AG; Teva Pharmaceuticals USACompletedInflammatory Breast Cancer | HER-2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III | Inflammatory Breast Cancer Stage IVGermany
-
German Breast GroupRoche Pharma AG; Amgen; Teva Pharmaceuticals USA; Vifor PharmaCompletedInflammatory Breast Cancer | HER2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage IIIGermany
-
Ludwig-Maximilians - University of MunichPierre Fabre LaboratoriesCompletedCarcinoma Breast Stage IVGermany
-
University Hospital TuebingenRecruitingBreast Carcinoma | Breast Carcinoma in SituGermany
-
SamanTree Medical SASt. Vincenz Krankenhaus GmbH, PaderbornCompletedBreast-Conserving Surgery | Breast Cancer - Ductal Carcinoma in Situ (DCIS)Germany
-
German Breast GroupCompleted
-
Pierre Fabre Pharma GmbHiOMEDICO AGCompletedMetastatic Breast Cancer | Non Small Cell Lung CarcinomaGermany
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast CancerGermany
-
University of MagdeburgBoehringer IngelheimTerminated
-
GlaxoSmithKlineCompletedNeoplasms, BreastUnited States, Canada, Germany, Spain, Taiwan, Belgium, Philippines, Israel, Hong Kong, Thailand, Pakistan, Russian Federation, Italy, Romania, China, France, Peru, United Kingdom, Czech Republic, Australia, Chile, Korea, Republic of and more
-
iOMEDICO AGNovartis Pharmaceuticals; Arbeitsgemeinschaft fur Internistische OnkologieCompletedBreast Cancer Recurrent | HER2/Neu-negative Carcinoma of Breast | Hormone Receptor Positive Malignant Neoplasm of BreastGermany
-
Fondazione MichelangeloCompletedInvasive Ductal Breast CarcinomaSpain, Ireland, Italy, Taiwan, Germany, Austria, Russian Federation
-
Kliniken Essen-MitteGerman Breast GroupCompletedEarly-Stage Breast CarcinomaGermany, Switzerland
-
University of JenaUniversity Hospital Erlangen; Labor Prof. PachmannRecruiting
-
West German Study GroupGlaxoSmithKlineTerminatedCarcinoma, Ductal, BreastGermany
-
University Hospital Schleswig-HolsteinUniversity of LuebeckActive, not recruitingEarly-Stage Breast CarcinomaGermany
-
AstraZenecaGerman Adjuvant Breast Cancer GroupCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Johannes Gutenberg University MainzCompletedCancer | Ulcerative Colitis | Intraepithelial NeoplasiaGermany
-
University of Erlangen-Nürnberg Medical SchoolRecruitingInflammatory Bowel DiseasesGermany
-
Immutep S.A.S.CompletedAdenocarcinoma Breast Stage IVNetherlands, United Kingdom, France, Belgium, Germany, Hungary, Poland
-
BioInvent International ABActive, not recruitingHER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | HER2-positive Metastatic Breast CancerSpain, United Kingdom, Germany
-
Klinikum LudwigshafenCompletedInflammatory Response | Hepatic FunctionGermany
-
University of Erlangen-Nürnberg Medical SchoolCompletedInflammatory Bowel DiseasesGermany
-
Palleos Healthcare GmbHRoche Pharma AG; University Hospital, Essen; University Hospital Erlangen; Phaon...Active, not recruitingTriple-negative Breast CancerGermany
-
University Hospital Schleswig-HolsteinCompletedSafety Issues | PharmacokineticGermany
-
West German Study GroupCelgeneActive, not recruiting
-
University Hospital MuensterUnknownInflammatory Bowel Diseases | Crohn DiseaseGermany
-
University Hospital TuebingenUniversity Hospital Freiburg; University Hospital UlmRecruitingTNBC - Triple-Negative Breast CancerGermany
-
photonamic GmbH & Co. KGTerminated
-
Universität Duisburg-EssenSozialstiftung Bamberg; Enterosan Labor LS SE & Co.KGRecruitingInflammatory Bowel DiseasesGermany
-
German Breast GroupCompleted
-
German Breast GroupTerminatedMetastatic Breast CancerGermany
-
AIO-Studien-gGmbHNovartis Pharmaceuticals; iOMEDICO AGCompletedHer2-negative Metastatic Breast Cancer | Her2-negative Locally Advanced Breast CancerGermany
-
University Hospital ErlangenUnknownInflammatory Bowel DiseaseGermany
-
University of CologneCompletedSystemic Inflammatory Response Syndrome (SIRS)Germany
-
Universitätsklinikum Hamburg-EppendorfCompletedCarcinomas of the Esophagogastric JunctionGermany
-
University of Erlangen-Nürnberg Medical SchoolCompletedInflammatory Bowel Diseases | Digestive System DiseaseGermany
-
Technical University of MunichEli Lilly and CompanyRecruitingBreast Cancer/ Metastatic Breast CancerGermany
-
German Breast GroupBoehringer IngelheimCompleted
-
Technical University of MunichCompletedQuality of Life in Patients With Inflammatory Bowel DiseaseGermany
-
Charite University, Berlin, GermanyRecruiting
-
German Breast GroupCompletedBreast Cancer MetastaticGermany
-
University of JenaCompleted
-
iOMEDICO AGRoche Pharma AG; Arbeitsgemeinschaft fur Internistische Onkologie; Arbeitskreis...CompletedMetastatic Breast CancerGermany
-
NovartisCompletedMetastatic Breast CancerGermany
-
Kliniken Essen-MitteRecruitingPrimary Breast CancerGermany
-
Prof. Wolfgang JanniRoche Pharma AG; Novartis Pharmaceuticals; Celgene Corporation; Eisai GmbHActive, not recruiting